Calgary, Alberta — February 3, 2026 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has appointed Dr. York Hsiang as a Business Consultant. The company is known as a leader in autologous stem cell therapies for conditions such as peripheral arterial disease and chronic limb threatening ischemia.
According to Thomas Smeenk, President & CEO of Hemostemix Inc., since 2006, when asking principal investigators if ACP-01 works, the answer has been an enthusiastic ‘Yes’. Smeenk noted that Dr. Hsiang added, ‘…in 30 years of medical practice I have not witnessed a therapy as effective as ACP-01.’
Dr. Hsiang said that ACP-01 is a dramatic game changer for suitable patients with no option critical threatening limb ischemia (CTLI), noting that in 30 years of practice he has not seen a therapy as effective as ACP-01. He added that for peripheral arterial disease patients, there are beneficial treatments to minimize pain and preserve function, however, for no option critical threatening limb ischemia (CTLI) patients, a timely amputation was the only procedure offered.
Dr. Hsiang, who was a Principal Investigator of Hemostemix’s Phase II clinical trial of ACP-01, is a globally respected vascular surgeon, and Professor Emeritus of Surgery at the University of British Columbia (UBC) Faculty of Medicine.
During his career, Dr. Hsiang has been a leader in vascular surgery, endovascular innovation, clinical epidemiology, and health-system governance in Canada.
Dr. Hsiang received his medical degree from the University of Otago, completed general and vascular surgery training at UBC, and pursued advanced training in health care evaluation and epidemiology through a Master’s degree and research fellowship at Harbor-UCLA. His leadership roles have included Division Head of Vascular Surgery at UBC, Associate Department Head of Surgery, and Managing Director of the Physician Staff Association at Vancouver Hospital, where he also introduced and scaled hospital-based endovascular surgery programs.
Dr. Hsiang has published extensively on vascular disease outcomes, surgical innovation, and health-system performance, and has collaborated in the development of novel vascular devices, including “smart” stent technologies for early restenosis detection. He has served as President of the Western Vascular Society and holds fellowships and distinctions across leading vascular and surgical organizations internationally.
Dr. Hsiang’s appointment also reflects a strategy developed through dialogue with Canada’s First Nations. Hemostemix is working collaboratively with First Nations to ensure that any joint venture or clinical presence on First Nations Territories is grounded in respect for Indigenous sovereignty and jurisdiction over healthcare, long-term economic stewardship, capacity-building, and physician-led, ethics-driven delivery of care for patients with no remaining conventional treatment options.
The goal is a collaborative, long-term business plan to establish destination healthcare on First Nations territories, positioning these communities as centers of healing based on clinical excellence, innovation, and international patient care blended with traditional cultural healing methodologies.
As Business Consultant, Dr. Hsiang will advise Hemostemix on joint ventures with First Nations governments, clinical staffing models, and strategic commercialization pathways in jurisdictions where Hemostemix has lawful access, including Canada, Florida under SB 1768 and The Bahamas’ regenerative medicine framework. He will also advise on ethical scale-up of ACP-01 for patients suffering from circulatory insufficiency who have exhausted conventional options.
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. The company has developed, patented, is scaling and selling autologous blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result.
Source: Hemostemix Inc.
